Clinical trial
Purified Rabies Vaccine for Human Use (Chick-embryo Cell)
NCT00345319 · Novartis Vaccines, Industry · Completed
Key facts
| NCT number | NCT00345319 |
|---|---|
| Title | Purified Rabies Vaccine for Human Use (Chick-embryo Cell) |
| Official title | Evaluate the Immunogenicity and Safety of Rabies Vaccine Given in a Post-exposure Prophylaxis Regimen to Healthy Children and Adults Aged 10-60 Years. |
| Lead sponsor | Novartis Vaccines, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Rabies Post-exposure Prophylaxis |
| Intervention type | Biological |
| Interventions | rabies vaccine |
| Enrollment | 630 |
| Start date | Mar 1, 2006 |
| Primary completion | May 1, 2006 |
| Completion | May 1, 2006 |
| First posted | Jun 28, 2006 |
| Last update posted | Dec 14, 2011 |
| Countries | China |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: